Compare · ENGN vs RVMD
ENGN vs RVMD
Side-by-side comparison of enGene Therapeutics Inc. (ENGN) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENGN and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $40.57B, about 354.0x ENGN ($114.6M).
- Over the past year, ENGN is down 82.1% and RVMD is up 229.0% - RVMD leads by 311.1 points.
- RVMD has been more active in the news (12 items in the past 4 weeks vs 2 for ENGN).
- RVMD has more recent analyst coverage (25 ratings vs 23 for ENGN).
- Company
- enGene Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $1.67-2.63%
- $178.07-5.91%
- Market cap
- $114.6M
- $40.57B
- 1M return
- -12.60%
- -9.54%
- 1Y return
- -82.11%
- +229.03%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 2
- 12
- Recent ratings
- 23
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ENGN
- enGene to Host KOL Webinar on October 15, 2026
- Interim Chief Medical Officer Grossman William bought $10,051 worth of shares (5,102 units at $1.97) (SEC Form 4)
- SEC Form 10-Q filed by enGene Therapeutics Inc.
- enGene Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
- enGene to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by enGene Therapeutics Inc.
Latest RVMD
- William Blair initiated coverage on Revolution Medicines
- Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)